RT Journal Article
T1 Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
A1 Brenner, Bluma G
A1 Thomas, Rejean
A1 Blanco, Jose Luis
A1 Ibanescu, Ruxandra-Ilinca
A1 Oliveira, Maureen
A1 Mesplede, Thibault
A1 Golubkov, Olga
A1 Roger, Michel
A1 Garcia, Federico
A1 Martinez, Esteban
A1 Wainberg, Mark A
K1 HIV Integrase Inhibitors
K1 Heterocyclic Compounds, 3-Ring
K1 Oxazines
K1 Piperazines
K1 Pyridones
AB Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine to dolutegravir monotherapy. The G118R mutation also arose in a treatment-experienced patient switched to dolutegravir monotherapy. The genetic basis for G118R selection and potential phenotypic outcome was ascertained. Genotypic analysis was performed on patients with virological failure ( We report on two patients who developed viral failure while on dolutegravir monotherapy. Both patients had been on a current or previous regimen containing integrase inhibitors. Virological failure ( Although resistance to dolutegravir is typically rare, genetic polymorphisms and monotherapy can facilitate the acquisition of G118R.
PB Oxford University Press
YR 2016
FD 2016-02-17
LK http://hdl.handle.net/10668/9956
UL http://hdl.handle.net/10668/9956
LA en
NO Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, et al. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother. 2016 Jul;71(7):1948-53.
NO This work was supported by grants from the Canadian Institutes for HealthResearch (CIHR) and Fonds de Recherche du Que´bec-Sante´ (FRQS)-Re´seauSIDA, and a Large-Scale Applied Research Project in Genomics andPersonalized Health HIV142 contract from Genome Canada to M. W. Thefunders played no decision-making role in the design, execution, and analysis or reporting of the research.
DS RISalud
RD Apr 7, 2025